• 1
    Baldus CD, Tanner SM, Ruppert AS et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood 2003; 102: 16138.
  • 2
    Baldus CD, Martus P, Burmeister T et al. Low ERG and BAALC expression identifies a new subgroup of adult acute t-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol 2007; 25: 373945.
  • 3
    Langer C, Radmacher MD, Ruppert AS et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 2008; 111: 53719.
  • 4
    Kuhnl A, Gokbuget N, Stroux A et al. High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood 2010; 115: 373744.
  • 5
    Heesch S, Schlee C, Neumann M et al. BAALC-associated gene expression profiles define IGFBP7 as a novel molecular target in acute leukemia. Leukemia 2010; 24: 142936.
  • 6
    Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 334.
  • 7
    Oh Y. IGFBPs and neoplastic models. New concepts for roles of IGFBPs in regulation of cancer cell growth. Endocrine 1997; 7: 1113.
  • 8
    Mutaguchi K, Yasumoto H, Mita K et al. Restoration of insulin-like growth factor binding protein-related protein 1 has a tumor-suppressive activity through induction of apoptosis in human prostate cancer. Cancer Res 2003; 63: 771723.
  • 9
    Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008; 132: 36374.
  • 10
    Sprenger CC, Vail ME, Evans K, Simurdak J, Plymate SR. Over-expression of insulin-like growth factor binding protein-related protein-1(IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis. Oncogene 2002; 21: 1407.
  • 11
    How HK, Yeoh A, Quah TC et al. Insulin-like growth factor binding proteins (IGFBPs) and IGFBP-related protein 1-levels in cerebrospinal fluid of children with acute lymphoblastic leukemia. J Clin Endocrinol Metab 1999; 84: 12837.
  • 12
    Vizioli MG, Sensi M, Miranda C et al. IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. Oncogene 2010; 29: 383544.
  • 13
    Komatsu S, Okazaki Y, Tateno M et al. Methylation and downregulated expression of mac25/insulin-like growth factor binding protein-7 is associated with liver tumorigenesis in SV40T/t antigen transgenic mice, screened by restriction landmark genomic scanning for methylation (RLGS-M). Biochem Biophys Res Commun 2000; 267: 10917.
  • 14
    Burger AM, Zhang X, Li H et al. Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. Oncogene 1998; 16: 245967.
  • 15
    Ruan W, Xu E, Xu F et al. IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis. Cancer Biol Ther 2007; 6: 3549.
  • 16
    Wilson HM, Birnbaum RS, Poot M, Quinn LS, Swisshelm K. Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. Cell Growth Differ 2002; 13: 20513.
  • 17
    Adachi Y, Itoh F, Yamamoto H et al. Expression of angiomodulin (tumor-derived adhesion factor/mac25) in invading tumor cells correlates with poor prognosis in human colorectal cancer. Int J Cancer 2001; 95: 21622.
  • 18
    Chen Y, Pacyna-Gengelbach M, Ye F et al. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumour-suppressive activity in human lung cancer. J Pathol 2007; 211: 4318.
  • 19
    Lin J, Lai M, Huang Q et al. Methylation patterns of IGFBP7 in colon cancer cell lines are associated with levels of gene expression. J Pathol 2007; 212: 8390.
  • 20
    Ruan WJ, Lin J, Xu EP et al. IGFBP7 plays a potential tumor suppressor role against colorectal carcinogenesis with its expression associated with DNA hypomethylation of exon 1. J Zhejiang Univ Sci B 2006; 7: 92932.
  • 21
    Tost J, Gut IG. Analysis of gene-specific DNA methylation patterns by pyrosequencing technology. Methods Mol Biol 2007; 373: 89102.
  • 22
    Gokbuget N, Raff R, Brugge-Mann M et al. Risk/MRD adapted GMALL trials in adult ALL. Ann Hematol 2004; 83(Suppl 1): S12931.
  • 23
    Schwartz S, Rieder H, Schlager B et al. Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10(−)/CD24(−)/CD65s(+)/CD15(+) B-cell pheno-type. Leukemia 2003; 17: 158995.
  • 24
    Heuser M, Beutel G, Krauter J et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 2006; 108: 3898905.
  • 25
    Heesch S, Goekbuget N, Stroux A et al. Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. Haematologica 2010; 95: 9429.
  • 26
    Mossner M, Hopfer O, Nowak D et al. Detection of differential mitotic cell age in bone marrow CD34(+) cells from patients with myelodysplastic syndrome and acute leukemia by analysis of an epigenetic molecular clock DNA signature. Exp Hematol 2010; doi:10.1016/j.exphem.2010.03.022.
  • 27
    Haferlach T, Kohlmann A, Wieczorek L et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010; 28: 252937.
  • 28
    Civin CI, Trischmann T, Kadan NS et al. Highly purified CD34-positive cells reconstitute hematopoiesis. J Clin Oncol 1996; 14: 222433.
  • 29
    Yin AH, Miraglia S, Zanjani ED et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90: 500212.
  • 30
    Miraglia S, Godfrey W, Yin AH et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997; 90: 501321.
  • 31
    Carow CE, Levenstein M, Kaufmann SH et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 1996; 87: 108996.
  • 32
    Ferrando AA, Neuberg DS, Staunton J et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1: 7587.
  • 33
    Ferrando AA, Look AT. Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematol 2003; 40: 27480.
  • 34
    Singal R, Ginder GD. DNA methylation. Blood 1999; 93: 405970.
  • 35
    Suzuki H, Igarashi S, Nojima M et al. IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis 2010; 31: 3429.
  • 36
    Bergmann L, Miething C, Maurer U et al. High levels of Wilms’ tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997; 90: 121725.
  • 37
    Gutierrez A, Sanda T, Ma W et al. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood 2010; 115: 284551.
  • 38
    Coustan-Smith E, Mullighan CG, Onciu M et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10: 14756.